HK Stock Market Move | REMEGEN (09995) rose by more than 4% and will disclose first-quarter performance at the end of the month. Positive data for the third phase of the MG study.

REMEGEN (09995) surged by over 4% again, with the stock price up more than 40% within the month. As of the time of writing, it has risen by 4.79%, reaching 35 Hong Kong dollars with a trading volume of 3.45 billion Hong Kong dollars. On the news front, REMEGEN announced that it will release its first quarter performance on April 28. In addition, the company recently announced the results of the Phase III trial of tabalumab for the treatment of generalized myasthenia gravis (gMG) in China in a verbal presentation at the American Academy of Neurology (AAN) annual meeting. The data showed that in 114 Chinese patients, after 24 weeks of treatment with tabalumab, 98.1% of patients had an improvement of 3 points in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which is clinically significant. BOCOM INTL believes that the Phase III data of tabalumab for gMG is superior to competing products on the market, and the commercial promotion strategy is clear. In contrast, Morgan Stanley International stated that although the positive Phase III data presents a commercial opportunity for MG, the inclusion of tabalumab in the medical insurance system is expected around 2026 or 2027, which is 2-3 years later than eculizumab. The bank believes that the short-term commercialization of MG still needs further validation.